### Strand Life Sciences Launches Revolutionary CancerSpot Test for Early Detection of Cancer

Bengaluru,  Strand Life Sciences, a leading genomics and bioinformatics company in India, has unveiled a groundbreaking blood-based test, CancerSpot, aimed at the early detection of multiple types of cancer. This innovative test leverages globally recognized methylation profiling technology to detect tumor DNA in its early stages. Strand Life Sciences operates as a subsidiary of Reliance Industries Limited.

The CancerSpot test identifies methylation signatures in cancer DNA present in the bloodstream using advanced genomic sequencing and analytical processes, offering a simple and convenient alternative for cancer screening.

Isha Ambani Piramal, Board Member of Reliance Industries Limited, stated, "Reliance remains committed to serving humanity and reshaping the future of healthcare. Strand’s new cancer detection test represents a significant step forward in health innovation."

Dr. Ramesh Hariharan, CEO of Strand Life Sciences, expressed pride in the development, saying, "Timely detection is critical in the fight against cancer. We are honored to introduce this transformative cancer detection solution."

The state-of-the-art Genomics Diagnostics and Research Center, spanning 33,000 square feet, was inaugurated by Dr. Charles Cantor, an eminent expert in genomics and biophysical chemistry. This new facility underscores Strand’s commitment to advancing diagnostic solutions and research in India.